Pharmacological and genetic blockade of Cx36-containing gap junctions dramatically reduce neuronal death in animal models of ischemia, TBI and epilepsy [6, 14–17] and prevent NMDA receptor (NMDAR)-mediated excitotoxicity [14, 18, 19]. Here, GJD2 is linked to ischemia.